Péptidos inhibidores del PSMA radiomarcados para el estudio del carcinoma de próstata.

Prostate cancer, with a high incidence and as the second cause of death among the male population, constitutes a serious health problem that worsens over the years. The early diagnosis and the correct staging of this disease are important for the adequate management of the patient. In this sense, Nuclear Medicine molecular imaging is very useful, so the development of new peptidomimetic molecules with affinity for membrane receptors overexpressed in prostate cancer, such as prostate specific antigen (PSMA), has allowed making a qualitative step forward for the early detection and monitoring of prostate carcinoma. The present work is aimed at providing an overview of the status of PSMA inhibitor peptides, derived from the sequence -Lys-Urea-Glu-, as radiopharmaceuticals for the study of prostate neoplasms, which are currently in different stages of development, showing, in general, a high specificity, an adequate uptake into the tumor tissue and a satisfactory pharmacokinetics, to be used in the study of prostate cancer, both by positron emission tomography (PET), and by single photon emission computed tomography (SPECT). [ABSTRACT FROM AUTHOR]